First Wave BioPharma Inc
NASDAQ:ENTO

Watchlist Manager
First Wave BioPharma Inc Logo
First Wave BioPharma Inc
NASDAQ:ENTO
Watchlist
Price: 3.55 USD 6.61% Market Closed
Market Cap: $11.9m

First Wave BioPharma Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

First Wave BioPharma Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
First Wave BioPharma Inc
NASDAQ:ENTO
Research & Development
-$38.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

First Wave BioPharma Inc
Glance View

Market Cap
11.9m USD
Industry
Biotechnology

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 17 full-time employees. The company went IPO on 2016-10-11. The firm is focused on developing its pipeline of gut-restricted GI clinical product candidates, including niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, which is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The firm is advancing two separate clinical programs of niclosamide formulations, both of which are in Phase II clinical trials, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis. The adrulipase programs is focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

ENTO Intrinsic Value
Not Available

See Also

What is First Wave BioPharma Inc's Research & Development?
Research & Development
-38.3m USD

Based on the financial report for Dec 31, 2021, First Wave BioPharma Inc's Research & Development amounts to -38.3m USD.

What is First Wave BioPharma Inc's Research & Development growth rate?
Research & Development CAGR 1Y
-101%

Over the last year, the Research & Development growth was -101%.

Back to Top